Thienopyrimidine and thienopyridine compounds and methods of use thereof

USRE49687E1 · kind E1 · reissue

Assignees

• THE REGENTS OF THE UNIVERSITY OF MICHIGAN · US
• Kura Oncology, Inc. · US

Inventors

• Jolanta Grembecka · Ann Arbor, US
• Tomasz Cierpicki · Ann Arbor, US
• Dmitry Borkin · Ann Arbor, US
• Jonathan Pollock · Ann Arbor, US
• Hongzhi Miao · Ann Arbor, US
• Duxin Sun · Ann Arbor, US
• Liansheng Li · San Diego, US
• Tao Wu · Carlsbad, US
• Jun Feng · San Diego, US
• Pingda Ren · San Diego, US
• Yi Liu · San Diego, US

Key dates

• Filing date: Feb 2, 2021
• Grant date: Oct 10, 2023
• Expiry date: Feb 2, 2041

Classification

• Technology area (CPC —): General

Abstract

The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.